On July 10, FDA announced it would resume prioritized domestic inspections based on a rating system of the COVID-19 virus trajectory in a given state and applicable local rules and regulations. The agency will also continue to utilize alternative means, such as record review, as well as relying on self-policing requirements such as cGMPs. This webinar will address tools the agency is using to ensure industry compliance during the COVID-19 pandemic and legal authority and limitations underlying these tools. The panelists will also discuss logistical and legal challenges facing industry in the context of inspections, and ways for industry to respond to these challenges.
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.